APA (7th ed.) Citation

Mohr, P., Debus, D., Wasielewski, I. v., Tüting, T., Gebhardt, C., Heppt, M. V., . . . Schadendorf, D. (2024). COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma. Annals of oncology, 35(Supplement 2), . https://doi.org/10.1016/j.annonc.2024.08.1167

Chicago Style (17th ed.) Citation

Mohr, Peter, et al. "COMBI-EU: Adverse Event Management of Adjuvant Dabrafenib Plus Trametinib (D+T) in Patients with BRAF V600-mutant Melanoma." Annals of Oncology 35, no. Supplement 2 (2024). https://doi.org/10.1016/j.annonc.2024.08.1167.

MLA (9th ed.) Citation

Mohr, Peter, et al. "COMBI-EU: Adverse Event Management of Adjuvant Dabrafenib Plus Trametinib (D+T) in Patients with BRAF V600-mutant Melanoma." Annals of Oncology, vol. 35, no. Supplement 2, 2024, https://doi.org/10.1016/j.annonc.2024.08.1167.